Experienced with advanced research techniques, critical thinking, and scholarly writing. Utilizes comprehensive knowledge in data analysis and literature review to drive research projects forward. Strong understanding of collaborative research processes and scientific method application in pediatric oncology.
1. Daartey, A. B., & Agarwal, S. (2025, April). Targeting epigenetic and oncogenic signaling in medulloblastoma: Comparative analysis of HDAC/PI3K dual targeting and HDAC inhibition [Poster presentation]. American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting, Arlington, VA. J Pharmacol Exp Ther, 392(3), 100543. https://doi.org/10.1016/j.jpet.2024.100543
2. Daartey, A. B., & Agarwal, S. (2025, April). Epigenetic and signaling pathway targeting: Enhanced efficacy of dual HDAC and PI3K inhibition over HDAC alone in in vitro and in vivo studies of medulloblastoma [Oral presentation]. St. John’s University Student Research Conference, Queens, NY
3. Daartey, A. B., & Agarwal, S. (2024, March). Dual targeting of PI3K and HDAC inhibits pediatric medulloblastoma growth [Oral presentation]. St. John’s University Research Conference, New York, NY
4. Daartey, A. B., Chilamakuri, R., & Agarwal, S. (2024, May). Adavosertib targets WEE1 and inhibits pediatric neuroblastoma growth [Poster presentation]. ASPET Annual Meeting, Arlington, VA. J Pharmacol Exp Ther, 389(S3), 048. https://doi.org/10.1124/jpet.048.934960
5. Suri, P., Daartey, A. B., & Agarwal, S. (2024, May). MDM2 targeting PROTAC stabilizes P53 and inhibits neuroblastoma growth [Poster presentation]. ASPET Annual Meeting, Arlington, VA. J Pharmacol Exp Ther, 389(S3), 447. https://doi.org/10.1124/jpet.447.919480
1. Doctoral fellowship (2025-2028),
2. Best Abstract travel Award for division of Cancer Pharmacology, ASPET Conference 2025
3. Educational Pathways International scholarship for undergraduate studies (2014-2020)